BiotechTube
Pelago Bioscience

Pelago Bioscience

Solna, Sweden· Est.
pelagobio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7.2M

Overview

Pelago Bioscience is a service provider specializing in CETSA®-based assays, offering critical target engagement data for drug discovery programs. Founded in 2016, the company has established a strong track record, serving over 350 customers, including top-tier pharmaceutical firms, and completing more than 750 projects. By measuring protein behavior in native cellular environments, Pelago's platform helps clients de-risk discovery, identify off-target effects, and make more informed decisions on lead optimization and translational studies.

Drug DeliveryProteomics

Technology Platform

Cellular Thermal Shift Assay (CETSA®) for measuring drug-target engagement and protein stability in live cells, tissues, and biofluids. Includes both targeted and unbiased mass spectrometry-based profiling.

Funding History

2
Total raised:$7.2M
Series A$6M
Seed$1.2M

Opportunities

Growing demand for cell-based target validation and off-target profiling in drug discovery, especially for complex targets.
Expansion into translational and in-vivo biomarker services for preclinical development.
Potential to develop standardized kits or instruments based on the CETSA® platform.

Risk Factors

Revenue dependent on fluctuating pharma R&D budgets and project-based work.
Competition from other target engagement technologies or CROs.
Risk of technological obsolescence if newer, superior methods emerge.

Competitive Landscape

Competes with other CROs offering biochemical and cell-based binding assays, as well as companies with alternative target engagement technologies (e.g., SPR, nanoBRET). Its key differentiator is the direct measurement of thermal stabilization in native cellular environments, which is unique to the CETSA® platform.

More companies in Sweden →